AuthorsCheadle, Eleanor J
AffiliationPaterson Institute for Cancer Research, Department of Medical Oncology, Wilmslow Road, Manchester M204BX, UK. Echeadle@picr.man.ac.uk
MetadataShow full item record
AbstractMicromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma. The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
CitationMT-103 Micromet/MedImmune. 2006, 8 (1):62-8 Curr. Opin. Mol. Ther.
JournalCurrent Opinion in Molecular Therapeutics
- Blinatumomab for the treatment of B-cell lymphoma.
- Authors: Oak E, Bartlett NL
- Issue date: 2015 May
- A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
- Authors: Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC
- Issue date: 2000 Mar 15
- Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
- Authors: Buie LW, Pecoraro JJ, Horvat TZ, Daley RJ
- Issue date: 2015 Sep
- CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
- Authors: Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA
- Issue date: 2007 Mar
- Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
- Authors: Dahl J, Mace M, Kantarjian H, Jabbour E
- Issue date: 2015 Apr